BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioPlus Co Ltd
Capital Expenditures
BioPlus Co Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Capital Expenditures
-₩96.6B
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Capital Expenditures
-₩37.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
SD Biosensor Inc
KRX:137310
|
Capital Expenditures
-₩80.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Capital Expenditures
-₩25.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-24%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Capital Expenditures
-₩16.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Capital Expenditures
-₩6.9B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
3%
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Capital Expenditures?
Capital Expenditures
-96.6B
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Capital Expenditures amounts to -96.6B KRW.
What is BioPlus Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-71%
Over the last year, the Capital Expenditures growth was -348%. The average annual Capital Expenditures growth rates for BioPlus Co Ltd have been -85% over the past three years , -71% over the past five years .
